

香港聯合交易所有限公司
(香港交易及結算有限公司全資附屬公司)

THE STOCK EXCHANGE OF HONG KONG LIMITED

(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

通告 CIRCULAR

Subject: Change of SSE-Listed China Connect Securities List, List of Eligible SSE Securities for Margin Trading and List of Eligible SSE Securities for Short Selling

Enquiry: Participant General Enquiry Hotline¹ (Tel : 2840 3626 E-mail : trd@hkex.com.hk)

With effect from 24 December 2025, BIOCYTOGEN PHARMACEUTICALS (BEIJING) (SSE Security Code: 688796) listed on Shanghai Stock Exchange ("SSE") will be added to the list of China Connect Securities.

Effective the same day, the above security will be added to the List of Eligible SSE Securities for Margin Trading and List of Eligible SSE Securities for Short Selling.

The aforementioned changes are also available on the "[Eligible Stocks](#)" section of the Connect Programmes webpage.

When providing services to clients on China Connect Securities, Exchange Participants are reminded to refer to the latest information including but not limited to the announcements issued by listed companies on the SSE website.

Olivia Mak
Senior Vice President
Trading Department
Operations Division

This circular has been issued in the English language with a separate Chinese language translation. If there is any conflict in the circulars between the meaning of Chinese words or terms in the Chinese language version and English words in the English language version, the meaning of the English words shall prevail.

¹All calls to and from the Participant General Enquiry Hotline may be recorded. HKEX Privacy Policy Statement is available [here](#).